ESC 365 - Mechanisms of the clinical benefits of SGLT2i in heart failure (EMPEROR-Pooled)

ESC Professional Premium Access

Mechanisms of the clinical benefits of SGLT2i in heart failure (EMPEROR-Pooled)

Session: Late-Breaking Science - Innovations in drug treatment

Topic: Pharmacotherapy

Speaker: Professor F. Zannad (Vandoeuvre-Les-Nancy, FR)

Event: ESC Congress 2022

Congress Presentation

Add to my library

About the speaker

Professor Faiez Zannad

University of Lorraine, Vandoeuvre-Les-Nancy (France)

103 presentations

4 followers

3 more presentations in this session

Lifetime prediction and Treatment Benefit in HFrEF (LIFE-HF).

Speaker: Doctor S. Koudstaal (Gouda, NL)

Genotype-Guided Oral P2Y12 Inhibitor Therapy Reduces Cumulative Ischemic Events Following Percutaneous Coronary Intervention - A Prespecified Secondary Analysis of the TAILOR-PCI Randomised Trial

Speaker: Doctor B. Ingraham (Rochester, US)

ENTRIGUE: Pegozafermin for the treatment of severe hypertriglyceridemia.

Speaker: Professor D. Bhatt (New York, US)

Access the full session

Late-Breaking Science - Innovations in drug treatment

Speakers: Professor F. Zannad, Doctor S. Koudstaal, Doctor B. Ingraham, Professor D. Bhatt

About the event

ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources